Hirayama Y, Matsunaga N, Tashiro J, Amemiya T, Iwasaki M
Department of Ophthalmology, Nagasaki University School of Medicine, Japan.
Clin Ther. 1990 May-Jun;12(3):230-5.
Patients with retinal artery or vein obstruction received 150 mg of bifemelane hydrochloride daily for 1 to 11 months and other treatment (urokinase, steroid hormone, hyperbaric oxygen, or laser photocoagulation) or the latter without bifemelane. After treatment with bifemelane, improvements in visual acuity were seen in 12 of 17 eyes with central retinal artery obstruction, in three of four eyes with central retinal vein obstruction, and in five of nine eyes with branch retinal vein obstruction. Among the patients not receiving bifemelane, improvements were seen in two of six patients with central retinal artery disease, in 14 of 27 eyes with central retinal vein obstruction, and in 13 of 28 eyes with branch retinal vein obstruction. It is concluded that bifemelane can be used to improve visual acuity in many patients with central retinal artery obstruction.
视网膜动脉或静脉阻塞患者每日服用150毫克盐酸比芬美兰，持续1至11个月，并接受其他治疗（尿激酶、类固醇激素、高压氧或激光光凝），或仅接受后者而不使用比芬美兰。使用比芬美兰治疗后，17只视网膜中央动脉阻塞眼中有12只视力改善，4只视网膜中央静脉阻塞眼中有3只视力改善，9只视网膜分支静脉阻塞眼中有5只视力改善。在未接受比芬美兰治疗的患者中，6例视网膜中央动脉疾病患者中有2例视力改善，27只视网膜中央静脉阻塞眼中有14只视力改善，28只视网膜分支静脉阻塞眼中有13只视力改善。结论是，比芬美兰可用于改善许多视网膜中央动脉阻塞患者的视力。
